上海后花园QTH

Bristol-Myers pays $19.5 million to settle illegal marketing charges

first_img GET STARTED Pharmalot Bristol-Myers pays $19.5 million to settle illegal marketing charges [email protected] By Ed Silverman Dec. 8, 2016 Reprints What’s included? What is it? Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. @Pharmalot STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. Tags legalpharmaceuticalsSTAT+ Ed Silverman The specter of illegal marketing continues to haunt the pharmaceutical industry as Bristol-Myers Squibb agreed to a $19.5 million settlement with 42 states to resolve charges of improperly promoting an antipsychotic medicine several years ago.The drug maker was accused of so-called off-label marketing, which refers to promoting a medicine for an unapproved use. In this case, Bristol-Myers allegedly touted Abilify to children, as well as elderly patients with symptoms of dementia and Alzheimer’s disease. However, the pill was not approved by the US Food and Drug Administration for the uses for which the company was targeting those populations. Log In | Learn More About the Author Reprints Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. First 30 days free. GET STARTEDlast_img read more